Fig. 1: B16 melanoma is a stroma-poor tumor compared to 4T1 breast cancer. | Communications Biology

Fig. 1: B16 melanoma is a stroma-poor tumor compared to 4T1 breast cancer.

From: Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer

Fig. 1: B16 melanoma is a stroma-poor tumor compared to 4T1 breast cancer.The alt text for this image may have been generated using AI.

Mice were implanted with 200,000 B16F10 cells (hereby referred to as B16 or B16 melanoma) injected intradermally or 200,000 4T1 cells injected subcutaneously (n = 5 mice/group). Tumors were harvested 10 days post tumor challenge and fixed for immunohistochemistry (IHC) prior to staining with picrosirius red (PR) and alpha-smooth muscle actin (αSMA). a Representative cross sections of B16 melanoma (left) and 4T1 breast (right) stained with hematoxylin and eosin (H&E, top), PR (middle), and αSMA (bottom). b Bar graphs demonstrate quantification of the staining of either PR or αSMA ± standard deviation (SD) following analysis by Halo software with supervision from a pathologist. *p < 0.05; ****p < 0.001.

Back to article page